Arrowhead Pharmaceuticals, Inc.

NasdaqGS:ARWR 株式レポート

時価総額：US$11.7b

Arrowhead Pharmaceuticals 過去の業績

過去 基準チェック /06

Arrowhead Pharmaceuticalsの収益は年間平均-7.5%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間34.1% 36%割合で 増加しています。

主要情報

-7.50%

収益成長率

-3.32%

EPS成長率

Biotechs 業界の成長17.04%
収益成長率36.04%
株主資本利益率-58.39%
ネット・マージン-47.79%
前回の決算情報30 Jun 2026

最近の業績更新

分析記事 • Feb 12

Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality

Arrowhead Pharmaceuticals, Inc.'s ( NASDAQ:ARWR ) earnings announcement last week was disappointing for investors...

Recent updates

ナラティブ更新 • Sep 03

ARWR: Phase 3 SHASTA Results And Voucher Plan Will Drive Repricing

Analysts have lifted Arrowhead Pharmaceuticals' fair value estimate from $85.00 to $100.00. They cite stronger conviction around plozasiran in severe hypertriglyceridemia, the Madrigal partnership, and recent Phase 3 SHASTA-3 and SHASTA-4 data that underpin higher projected profit margins despite slightly softer revenue growth assumptions and a higher future P/E.
ナラティブ更新 • Aug 19

ARWR: SHTG Phase 3 Success And PRV Use Will Drive Future Upside

Arrowhead Pharmaceuticals' updated analyst price target has moved from about $89 to about $110. Analysts point to stronger assumptions around plozasiran in severe hypertriglyceridemia, the Madrigal partnership and the planned $215m priority review voucher purchase as key drivers of the revised valuation inputs.
ナラティブ更新 • Aug 05

ARWR: Cardiometabolic RNAi Readouts In Severe Hypertriglyceridemia Will Drive Future Repricing

Arrowhead Pharmaceuticals' updated analyst price target of $126, up from $110, reflects analysts' higher modeled revenue growth and confidence in plozasiran following positive SHASTA-3 and SHASTA-4 Phase 3 data. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals shows a cluster of higher price targets and supportive commentary tied directly to the Phase 3 SHASTA-3 and SHASTA-4 results for plozasiran in severe hypertriglyceridemia.
Seeking Alpha • Jul 22

Arrowhead Pharmaceuticals: Redemplo Meets High Expectations In SHTG Trials

Summary Arrowhead Pharmaceuticals reported positive phase 3 results for Redemplo, achieving 79-81% triglyceride reductions and significant acute pancreatitis risk reduction in severe hypertriglyceridemia. Redemplo demonstrates strong efficacy, quarterly dosing, and a favorable safety profile versus Ionis’ Tryngolza, positioning ARWR for leadership in the SHTG market. Tryngolza has a first-mover advantage and administration with an autoinjector versus the current prefilled syringe for Redemplo, but ARWR expects to have an autoinjector as well. I expect modest near-term sales from the small FCS market, with significant revenue potential upon SHTG launch following sNDA submission and likely approval by late 2027. Read the full article on Seeking Alpha
ナラティブ更新 • Jul 21

ARWR: Upcoming SHASTA-3 And 4 Results Will Drive Bullish Repricing

Arrowhead Pharmaceuticals' updated fair value estimate has been lifted from $57.11 to $85.00 as analysts factor in higher Street price targets in the $95 to $98 range, supported by growing optimism around upcoming SHASTA-3/4 data for plozasiran and its potential in severe hypertriglyceridemia. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals centers on the upcoming SHASTA-3/4 data readout for plozasiran in severe hypertriglyceridemia, with several firms updating price targets as they reassess the company’s risk and opportunity profile.
ナラティブ更新 • Jul 07

ARWR: Cardiometabolic Progress And EU Approval Will Support But Not Eliminate SHTG Uncertainty

Arrowhead Pharmaceuticals' analyst price targets have moved higher into the mid $40s, with analysts pointing to updated assumptions on fair value, profitability and revenue trends as key reasons for the reset. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals points to a cluster of price target increases and rating changes that frame how analysts are thinking about valuation, execution risk, and growth potential at current levels in the mid $40s.
ナラティブ更新 • Jun 23

ARWR: Mixed Wave Data And Execution Risks Will Challenge Recent Rebound

Analysts have lifted their price expectations for Arrowhead Pharmaceuticals. The updated fair value estimate has moved from $42.57 to $57.11 as they factor in a slower anticipated revenue decline, a higher projected profit margin, and a slightly lower future P/E multiple.
分析記事 • Jun 20

Arrowhead Pharmaceuticals (ARWR) Stock Could Be 25.6% Undervalued After R And D Webinar Update

Arrowhead Pharmaceuticals (ARWR) recently outlined a Summer Series of R&D webinars focused on its cardiometabolic pipeline, alongside positive clinical updates and upcoming regulatory milestones that have drawn fresh attention to the stock. See our latest analysis for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals’ recent R&D webinar announcement and positive late May clinical readouts have coincided with strong momentum, including a 45.25% 3 month share price return and a very large 1...
ナラティブ更新 • Jun 08

ARWR: Cardiometabolic RNAi Readouts And Licensing Will Drive Future Repricing

Arrowhead Pharmaceuticals' updated analyst price target moves to $46, up from $35, as analysts factor in modestly higher long term growth and margin assumptions, along with a slightly lower discount rate, while keeping fair value unchanged at $110. Analyst Commentary Recent Street research around Arrowhead points to a constructive shift in tone, with a series of bullish analysts highlighting upside drivers tied to execution on the pipeline and the broader biotech backdrop.
ナラティブ更新 • May 25

ARWR: Cardiometabolic RNAi Data And Licensing Will Drive Future Repricing

Analysts have raised Arrowhead Pharmaceuticals' average price target by $11 to $46, citing a stronger sector backdrop, healthier biotech funding conditions, and reassessed growth and profitability assumptions. These are reflected in higher revenue growth expectations and a slightly higher future P/E multiple.
ナラティブ更新 • May 07

ARWR: Cardiometabolic RNAi Data And Licensing Progress Will Drive Future Repricing

Analysts have raised their Arrowhead Pharmaceuticals price target by $12 to $110, citing updated assumptions for a less severe revenue contraction, higher projected profit margins, and a lower forward P/E estimate in recent research. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals has reflected a mix of caution and renewed optimism, with several bullish analysts focusing on price target changes, upgrades, and the implications for valuation and execution risk.
ナラティブ更新 • Apr 21

ARWR: Wave Data Concerns Will Test Sustainability Of Recent Share Price Rebound

Arrowhead Pharmaceuticals' analyst price target has edged higher by about $0.26 to $42.57, with analysts pointing to updated views on profit margins and P/E assumptions following a mix of recent target raises and trims across the Street. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals reflects a split view, with some firms lifting targets sharply and others trimming expectations.
ナラティブ更新 • Apr 06

ARWR: RNAi Obesity And Cardiometabolic Data Will Drive Future Repricing

Narrative update on Arrowhead Pharmaceuticals The consensus analyst price target for Arrowhead Pharmaceuticals has been adjusted to $110. This reflects mixed recent research that pairs questions around Wave Life Sciences data with higher targets from several firms citing early obesity program results and the Redemplo launch.
ナラティブ更新 • Mar 23

ARWR: Obesity RNAi Data And Cardiometabolic Franchise Will Drive Future Repricing

Analysts have updated their views on Arrowhead Pharmaceuticals with a revised blended price target of $110. This reflects mixed shifts in assumptions around discount rate, revenue growth, profit margins and future P/E after recent obesity and cardiometabolic data, as well as the Redemplo launch.
ナラティブ更新 • Mar 09

ARWR: Obesity RNAi Data Will Test Sustainability Of Recent Share Price Rebound

Analysts have reduced their blended price target on Arrowhead Pharmaceuticals by about $2 to reflect a lower fair value estimate of $42.31. This incorporates more cautious assumptions on near term revenue growth and margins, even as recent research notes highlight supportive early obesity data and emerging cardiometabolic opportunities.
ナラティブ更新 • Feb 22

ARWR: Obesity And Cardiometabolic Pipeline Progress Will Drive Future Repricing

Narrative Update: Arrowhead Pharmaceuticals The updated analyst price framework for Arrowhead Pharmaceuticals keeps fair value at $110 while trimming implied future P/E assumptions, reflecting analysts' mixed but generally constructive reaction to recent obesity and cardiometabolic data and the Redemplo launch. Analyst Commentary Recent research updates on Arrowhead Pharmaceuticals cluster around two themes you should keep in mind: confidence in the obesity and cardiometabolic pipeline, and growing interest in the early commercial rollout of Redemplo.
分析記事 • Feb 12

Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality

Arrowhead Pharmaceuticals, Inc.'s ( NASDAQ:ARWR ) earnings announcement last week was disappointing for investors...
ナラティブ更新 • Feb 08

ARWR: Obesity Pipeline Progress Will Drive Future Repricing In My View

Analysts raised their fair value estimate for Arrowhead Pharmaceuticals to $110 from $80 as they incorporate updated assumptions on Redemplo's launch, initial obesity pipeline data, and a lower projected future P/E multiple, while also reflecting slightly higher risk and more conservative expectations for revenue growth. Analyst Commentary Bullish analysts are leaning into Arrowhead's transition from a pure development story toward one with its first approved product and an emerging obesity pipeline, and they are adjusting their models to reflect both assets.
ナラティブ更新 • Jan 25

ARWR: Early Obesity RNAi Data Will Challenge Durability Of Recent Share Repricing

Narrative update on Arrowhead Pharmaceuticals The updated analyst price target for Arrowhead Pharmaceuticals shifts to reflect a fair value of $44.02. Analysts point to Redemplo's approval and launch, early data from the ARO INHBE and ARO ALK7 obesity programs, and increased confidence in the pipeline as key factors in their revised outlook.
ナラティブ更新 • Jan 11

ARWR: Obesity RNAi Data Will Test Sustainability Of Recent Share Repricing

Arrowhead Pharmaceuticals' analyst fair value estimate moved from $17.00 to about $44.94, as analysts cited early obesity trial data for ARO INHBE and ARO ALK7, validation of the TRiM RNAi platform, and the first FDA approval of Redemplo as key reasons for higher price targets in the US$80 range. Analyst Commentary Street research around Arrowhead has tilted more constructive around the obesity franchise, with multiple firms lifting their fair value estimates into the US$80 range after the initial ARO INHBE and ARO ALK7 data.
ナラティブ更新 • Dec 18

ARWR: Upcoming SHTG Readouts Will Temper Optimism Despite Recent Cardiometabolic Progress

Analysts have raised their price targets on Arrowhead Pharmaceuticals by roughly $6 to the mid $40s to low $60s range, citing the FDA approval of Redemplo, a strengthened commercial outlook in familial chylomicronemia syndrome and sHTG, and underappreciated long term cost and margin advantages. Analyst Commentary Bullish analysts view Redemplo's FCS approval as a key de-risking event that supports higher valuation multiples and justifies recent price target increases into the high $40s to low $60s range.
ナラティブ更新 • Dec 04

ARWR: Upcoming SHTG Data Will Likely Undermine Optimistic Cardiometabolic Expectations

Analysts have nudged their average price target on Arrowhead Pharmaceuticals higher to about $58 from $55, citing the FDA approval of Redemplo, expectations for a broader sHTG label, and underappreciated long term cost and margin advantages. Analyst Commentary Research coverage following the Redemplo approval has generally tilted positive, with several firms lifting their price targets and highlighting both the commercial opportunity in sHTG and Arrowhead's long term margin profile.
分析記事 • Dec 02

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shares have continued their recent momentum with a 33% gain in the last...
ナラティブ更新 • Nov 20

ARWR: FDA Milestone Will Drive Cost Advantage In Cardiometabolic Markets

Analysts have raised Arrowhead Pharmaceuticals' fair value estimate from $47.50 to $55.00 per share after the FDA approved Redemplo and expressed increased confidence in the company's commercial execution and cost advantages. Analyst Commentary Following the recent FDA approval of Redemplo, analysts have provided updated perspectives on Arrowhead Pharmaceuticals' valuation and prospects.
ナラティブ更新 • Nov 06

ARWR: Expect Cost Efficiency To Drive Competitive Advantage In Upcoming Metabolic Trials

Analysts have significantly raised their price target for Arrowhead Pharmaceuticals, increasing it from $38 to $61 per share. They cite structural cost advantages and an underappreciated long-term gross margin potential as key factors for this change.
ナラティブ更新 • Oct 22

Analysts Boost Arrowhead Pharmaceuticals Price Target Amid Cost Advantages and Strategic Partnerships

Arrowhead Pharmaceuticals' analyst price target has been raised from $45 to $47.50 per share. Analysts highlight the company's structural cost advantages and improved margin outlook.
分析記事 • Oct 07

What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You

Despite an already strong run, Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shares have been powering on, with a...
ナラティブ更新 • Oct 05

RNAi Pipeline Will Unlock Emerging Markets Despite Regulatory Risks

Analysts have slightly lowered their price target for Arrowhead Pharmaceuticals from $46.15 to $45.00, citing ongoing concerns following recent strategic divestitures by partners and modest shifts in the company's projected financials. Analyst Commentary Recent analyst research provides a mixed outlook for Arrowhead Pharmaceuticals following notable events involving partner Sarepta Therapeutics.
ナラティブ更新 • Sep 08

RNAi Pipeline Will Unlock Emerging Markets Despite Regulatory Risks

The consensus price target for Arrowhead Pharmaceuticals has increased modestly as its Future P/E has risen and Net Profit Margin has declined, resulting in a new analyst fair value of $46.15. What's in the News Arrowhead Pharmaceuticals announced a major global licensing and collaboration agreement with Novartis for ARO-SNCA, its preclinical siRNA therapy for synucleinopathies such as Parkinson’s Disease; the deal includes a $200 million upfront payment to Arrowhead, potential milestones up to $2 billion, and future royalties, with closing expected in the second half of 2025 (Key Developments).

収支内訳

Arrowhead Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGS:ARWR 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 26669-320189707
31 Mar 26622-301172672
31 Dec 251,091202157633
30 Sep 25829-2139593
30 Jun 25573-148129552
31 Mar 25545-144122542
31 Dec 243-640117512
30 Sep 244-599113491
30 Jun 2420-539116450
31 Mar 2435-471114395
31 Dec 23182-297108373
30 Sep 23241-205104342
30 Jun 23256-181117320
31 Mar 23273-150125298
31 Dec 22278-155135301
30 Sep 22243-176132289
30 Jun 22250-154141269
31 Mar 22263-112123258
31 Dec 21144-183104228
30 Sep 21138-14185202
30 Jun 21108-12664178
31 Mar 2189-11056151
31 Dec 2080-10355137
30 Sep 2088-8554127
30 Jun 20124-2452105
31 Mar 20139104691
31 Dec 19164533584
30 Sep 19169682781
30 Jun 19137462572
31 Mar 1995102366
31 Dec 1847-292058
30 Sep 1816-541953
30 Jun 1814-541851
31 Mar 1822-441651
31 Dec 1731-351354
30 Sep 1731-342049
30 Jun 1723-462549
31 Mar 1713-603246
31 Dec 164-754240
30 Sep 160-822561
30 Jun 160-844139
31 Mar 160-814037
31 Dec 150-893639
30 Sep 150-923547

質の高い収益: ARWRは現在利益が出ていません。

利益率の向上: ARWRは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: ARWRは利益が出ておらず、過去 5 年間で損失は年間7.5%の割合で増加しています。

成長の加速: ARWRの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: ARWRは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 64.6% ) と比較することは困難です。

株主資本利益率

高いROE: ARWRは現在利益が出ていないため、自己資本利益率 ( -58.39% ) はマイナスです。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/09/13 06:31
終値2026/09/11 00:00
収益2026/06/30
年間収益2025/09/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Arrowhead Pharmaceuticals, Inc. 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。28

アナリスト機関
Ying HuangBarclays
Jason Matthew GerberryBofA Global Research
Mayank MamtaniB. Riley Securities, Inc.